Compare FUSB & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUSB | PMN |
|---|---|---|
| Founded | 1952 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.4M | 84.1M |
| IPO Year | 1995 | 2022 |
| Metric | FUSB | PMN |
|---|---|---|
| Price | $15.75 | $9.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $42.71 |
| AVG Volume (30 Days) | 6.3K | ★ 38.0K |
| Earning Date | 10-28-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.15 | $0.29 |
| 52 Week High | $16.99 | $27.40 |
| Indicator | FUSB | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 27.95 |
| Support Level | $15.75 | $9.20 |
| Resistance Level | $16.92 | $15.37 |
| Average True Range (ATR) | 0.21 | 1.00 |
| MACD | 0.00 | -0.38 |
| Stochastic Oscillator | 84.37 | 4.66 |
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.